中国癌症杂志 ›› 2020, Vol. 30 ›› Issue (4): 293-298.doi: 10.19401/j.cnki.1007-3639.2020.04.008

• 论著 • 上一篇    下一篇

血清纤维蛋白降解复合物(DR-70)检测在结直肠癌患者中的诊断价值

开今言 1 ,马 倩 1 ,童 颖 1 ,谢素红 1 ,何成彦 2 ,宋丽娜 2 ,孙 静 3 ,朱广博 3 ,卢仁泉 1 ,郭 林 1   

  1. 1. 复旦大学附属肿瘤医院检验科,复旦大学上海医学院肿瘤学系,上海 200032;
    2. 吉林大学中日联谊医院检验科,吉林 长春 130033;
    3. 天津市人民医院检验科,天津 300000
  • 出版日期:2020-04-30 发布日期:2020-05-12
  • 通信作者: 郭 林 E-mail: guolin500@hotmail.com

Diagnostic value of serum fibrin degradation complex (DR-70) in patients with colorectal cancer

KAI Jinyan 1 , MA Qian 1 , TONG Ying 1 , XIE Suhong 1 , HE Chengyan 2 , SONG Lina 2 , SUN Jing 3 , ZHU Guangbo 3 , LU Renquan 1 , GUO Lin 1   

  1. 1. Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; 2. Department of Clinical Laboratory, China-Japan Union Hospital of Jilin University, Changchun 130033, Jilin Province, China; 3. Department of Clinical Laboratory, Tianjin People’s Hospital, Tianjin 300000, China
  • Published:2020-04-30 Online:2020-05-12
  • Contact: GUO Lin E-mail: guolin500@hotmail.com

摘要: 背景与目的:DR-70为纤维蛋白降解复合物,是肿瘤细胞释放的纤溶酶和凝血酶或其他肿瘤相关过程的降解产物,探讨其作为结直肠癌肿瘤标志物的潜在应用价值。方法:收集2016年10月—2017年12月复旦大学附属肿瘤医院、天津市人民医院、吉林大学中日联谊医院收治的具有完整临床病理学资料、经病理学或细胞学、影像学检查确诊的结直肠癌患者为研究对象,患者血清分为疾病组(215例结直肠癌患者)和对照组(30例良性胃肠道疾病患者和440名健康人),确定临界值,同时检测癌胚抗原(carcinoembryonic antigen,CEA)水平,分析其与结直肠癌患者临床特征之间的关系。对43例结直肠癌患者术前及术后化疗过程中的DR-70水平进行动态观察。结果:与对照组相比,结直肠癌患者血清DR-70水平显著升高(P<0.05);CEA和DR-70联合检测时,在CEA阳性条件下,DR-70弱阳性时,肠癌多发于结肠,而DR-70强阳性时,肠癌明显多发于直肠;肠癌患者术后化疗有效时,血清DR-70水平显著下降。结论:血清DR-70是结直肠癌诊断的一个潜在标志物,并且可以作为该类患者术后化疗效果判断的一个良好指标。

关键词: DR-70, 酶联免疫吸附试验, 结直肠癌

Abstract: Background and purpose: DR-70 is a fibrin degradation complex, which is a degradation product of plasmin and thrombin released by tumor cells or other tumor-related processes. This article explored its potential application value as a tumor marker for colorectal cancer. Methods: Serum samples were collected from the disease group (215 patients with colorectal cancer) and the control group (30 patients with benign gastrointestinal disease and 440 healthy people) in Fudan University Shanghai Cancer Center, China-Japan Union Hospital of Jilin University, and Tianjin People’s Hospital to determine the cut-off value; combined with the carcinoembryonic antigen (CEA) level, its relation with clinical characteristics of colorectal cancer patient was analyzed. The DR-70 levels of 43 patients with colorectal cancer before and after chemotherapy were followed up. Results: Compared with the control group, the serum DR-70 level of colorectal cancer patient was significantly increased (P<0.05). Under carcinoembryonic (CEA) positive conditions following combined detection of CEA and DR-70, colon cancer was more common when DR-70 was weakly positive, while rectal cancer was more common when DR-70 was strongly positive. When chemotherapy was effective in patients with colorectal cancer, serum DR-70 levels were significantly reduced. Conclusion: Serum DR-70 is a potential marker for the diagnosis of colorectal cancer and can be used as a good indicator for judging the curative effect of postoperative chemotherapy in this type of patient.

Key words: DR-70, Enzyme-linked immunosorbent assay, Colorectal cancer